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Summary High molecular weight tropomyosins (tms) are commonly down-regulated in fibroblasts
transformed by oncogenes. Previous studies have also demonstrated that specific tm isoforms are down-
regulated in human breast carcinoma cell lines. We examined tropomyosin isoforms in cells prepared from non-
cancerous breast lesions and primary human breast carcinomas. The average level of expression of all three
high molecular weight tm isoforms (tm 1-3) in carcinomas was generally found to be less than 25% of that
observed in non-cancerous breast lesions. Interestingly, the expression of tm 1 was found to be 1.7-fold higher
in primary tumours with metastatic spread to axillary lymph nodes compared with primary tumours with no
evidence of metastasis (P<0.05). Similarly, tm 1 expression was higher in two 12V-H-ras transformed
fibroblast cell lines capable of experimental metastasis compared with three weakly metastatic cell lines. We
conclude from these studies that expression of high molecular weight tm isoforms is low in primary breast
carcinomas, and that metastatic tumours express relatively high levels of tm 1.
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The synthesis of several microfilament-associated proteins,
including tropomyosin (tm) (Hendricks and Weintraub,
1981), vinculin (Raz and Geiger, 1982), a-actinin (Gluck et
al., 1993) and gelsolin (Vanderkerckhove et al., 1990) is
suppressed in transformed fibroblasts. Down-regulation of
some of these proteins has also been reported in transformed
epithelial cells and in breast carcinoma cell lines (Bhatta-
charya et al., 1988; Vanderkerckhove et al., 1990).
Tropomyosin isoform expression involves the use of
multiple genes, but diversity is also generated by alternative
processing of mRNA (Lees-Miller and Helfman, 1991). Four
different tropomyosin genes have been characterised in
mammals (a-TM, fl-TM, TM-4 and hTMnm). The terminol-
ogy for tm proteins used here is the one used for fibroblast
tms. Tropomyosins 1, 2 and 3 correspond to the high
molecular weight tms (284 amino acids), which are
homologous to tms expressed in muscle cells. Tropomyosins
4 and 5 have a lower molecular weight (247-248 amino
acids) and are characteristic of non-muscle cells.
Down-regulation of expression of the high molecular
weight tm isoforms accompanies neoplastic transformation
of murine and avian fibroblasts by a variety of retroviral
oncogenes, chemical mutagens and transforming growth
factors. It has been suggested that down-regulation of
tropomyosin expression in tumour cells may decrease
microfilament stability owing to increased susceptibility to
depolymerising factors. The loss of microfilament structure
may lead to altered cell shape, motility and altered
interaction with extracellular supporting elements (Cooper
et al., 1987; Lees-Miller and Helfman, 1991). Interestingly,
forced expression of tm 1 or tm 2 in tumour cells by the
introduction of cDNA expression vectors suppresses malig-
nant growth (Prasad et al., 1993) or causes an altered cellular
morphology (Takenaga and Masuda, 1994).
Previous work has established that cell lines derived from
human breast carcinomas show alterations in tm expression
(Bhattacharya et al., 1990). Tropomyosin 1 was found to be
absent in cell lines, and tms 2 or 3 were also frequently
absent. Whether such alterations in tm expression are
restricted to in vitro cultured cells or are also observed in
primary tumours has not yet been clarified. In the present
study we analysed tm isoform expression in non-cancerous
breast lesions and in primary human breast carcinomas. We
observed low levels of expression of all three high molecular
weight tm isoforms in carcinomas. Furthermore, the level of
tm 1 was found to be significantly higher in primary breast
carcinomas that had given rise to lymph node metastasis
compared with lymph node-negative tumours.
Materials and methods
Cell culture
Bt-549, MDA-MB-134, MDA-MB-231, SK-BR-3, ZR-75-30,
MCF7 and T47D human breast carcinoma cells, Hs-578 Bst
normal breast cells, WI38 and HDF human fibroblasts were
obtained from the American Type Culture Collection
(ATCC) and grown as recommended. Transformed rat
fibroblast cell lines (BRN-1, -2, -4, -6 and -7) were derived
from the transfection of rat embryo fibroblasts with polyoma
large-T antigen and T24-H-ras (Engel et al., 1993). These
cells were maintained in Dulbecco's modified Eagle medium
(DMEM) supplemented with 5% fetal calf serum, 2 mM
glutamine, penicillin (100 units ml-') and streptomycin
(100 yg ml-') (reagents from Flow Laboratories, Irvine,
UK) at 37'C/7% carbon dioxide.
Tumour tissue samples
Twenty malignant breast tumours (ten node-negative and ten
node-positive) were analysed. In addition, we examined five
non-cancerous breast lesions (three fibroadenomas, one
hamartoma and one ductal hyperplasia).
Non-necrotic tumour tissue was processed for two-
dimensional electrophoresis (2-DE) as previously described
(Franzen et al., 1993). Material from human breast lesions
were collected immediately after resection. Tumours were cut
and cells from a macroscopically viable area were collected
by scraping with a scalpel and then were resuspended in ice-
cold L15 medium supplemented with 5% calf serum.
Scraping was found to preferentially detach tumour cells
from the tissue (as revealed by staining of smears and
sections). Samples were further enriched for tumour cells by
removal of connective tissue by filtering of erythrocytes by
centrifugation in Percoll. Serum proteins were removed by
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repeated washing in phosphate-buffered saline (PBS). All
steps were performed on ice in the presence of protease
inhibitors. Cells were lysed in a sodium dodecyl sulphate
(SDS)-containing buffer, treated with DNAase and RNAase,
and dissolved in sample buffer containing detergents (NP40
and CHAPS) as described (Franzen et al., 1993). Staining of
cells extracted from carcinomas showed that these were
usually >90% lesion-specific cells, free from stromal
fibroblasts and other contaminating cells.
Electrophoresis
2-DE was performed by standard procedures as described
(Anderson, 1988; Franzen et al., 1993). Resolyte (2%, pH 4-
8, BDH) was used for isoelectric focusing, and 10% or 10-
13% linear gradient SDS-polyacrylamide gels in the second
dimension. Gels were stained with silver nitrate according to
standard procedures.
Identification of tm isoforms
Tropomyosins were purified from W138 fibroblasts as
described by Matsumura and Yamashiro-Matsumura
(1985). Purified protein was mixed with breast carcinoma
(MDA-MB-231) extracts and subjected to 2-DE. In addition,
2-DE maps were prepared from WT2 embryonal rat
fibroblasts and matched with the REF52 database (Garrels
and Franza, 1989). In all analyses, tm isoforms were
identified by matching the migration of protein with a
reference pattern (Figure la-c) using PDQUEST software.
Scanning and image analysis
2-DE gels were scanned at 100 yrm resolution using a PD
laser densitometer from Molecular Dynamics. Data were
analysed using the PDQUEST software (Garrels et al., 1984)
(Pharmacia Biotech, Uppsala, Sweden). Background was
subtracted, peaks located and quantitated. Tropomyosin 5
was used as standard for normalisation. The levels of tm 5
were found to parallel the levels of a number of other
proteins expressed at similar levels (as their fraction of total
integrated optical density in the gels) in 12 cases in which
total 2-DE patterns were analysed. One of these proteins was
identified as elongation factor lfl. It was found previously
that tm 5 is insensitive to transformation and growth
conditions (Garrels and Franza, 1989). We therefore chose
to use tm 5 as an internal standard for quantitation (quantity
of tm 5 =100 units).
Results
Analysis of tm isoforms in human breast carcinoma tumours
Tumour cells were extracted from non-cancerous human
breast lesions and breast carcinoma tissue and prepared for
2-DE. Tm polypeptides were identified by co-electrophoresis
of purified proteins and by matching with the REF52
database. Five tropomyosin isoforms were resolved (Figure
1) and the relative amounts of these polypetides were
determined by scanning and quantified using PDQUEST
software (Garrels et al., 1984). As shown in Figure 2 and
Table I, the expression of the high molecular weight tms
(tm 1, tm 2 and tm 3) was 4-5 fold higher in non-cancerous
lesions compared with carcinomas. These differences were
statistically significant for each protein at the level of P<0.05
(Mann-Whitney). Higher levels of tm 1 and tm 2 were
observed in all three cases of fibroadenoma and in the single
case of ductal hyperplasia compared with any of the cases of
carcinoma (Table I and Figure 2). An intermediate level of
tm 2 was observed in the single case of ductal hyperplasia, a
Figure 1 Panel of the tm area from 2-DE gels representing; a reference pattern for PDQUEST analysis showing tm isoforms 1-5
(a), WI-38 fibroblasts, total proteins (b) and tm isoforms 1-5 purified from WI-38 fibroblasts (c). Non-cancerous breast lesions (d-
g); fibroadenomas (d-e), hamartoma (f) and an intraductal hyperplasia (g). Node-negative (h-k) and node-positive carcinomas of
the breast (l-p). Each 2-DE gel is shown with the acidic side on the left hand. Numbers indicate the appropriate tm isoform, when
detectable (compare c). Circles indicate the expected position of tms.Tropomyosin isoforms in breast carcinoma
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Figure 2 Histogram showing relative expression levels of tm
isoforms 1-3 in non-cancerous ([L) and cancerous (-) breast
lesions. The average and standard deviation of five and 20 cases
respectively is presented. Significantly lower levels of tms 1-3
were observed in breast carcinomas.
breast lesion that can be considered as a precancerous lesion.
The expression of tm 3 was highly variable between
carcinomas (3.5-71 units). In three carcinomas, the levels
of tm 3 were found to be higher than the level observed in
the ductal hyperplasia. The levels of tm 4 did not significantly
differ between fibroadenomas and carcinomas (not shown).
Tm 5 was used as an internal standard for quantitation (see
Materials and methods).
The expression of tropomyosin isoforms was examined in
seven human breast carcinoma cell lines, in breast derived
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Figure 3 Histogram showing relative expression levels of
tropomyosin isoforms 1-3 in node-negative (El) and node-
positive (U) breast carcinomas. The average and standard
deviation of ten cases from each group is presented. A
significantly higher level of tm 1 was observed in node-positive
cases (*).
Table I Levels of high-Mr tms in clinical breast material (relative integrated optical density, tm 5= 100 units)
tMI tm2 tm 3
Breast carcinomas (n =20) 13 7.7 27 (ductal, invasive)
(0.9-27) (0- 14) (3.5-71)
Non-cancerous breast lesions (n=5) 62 39 103
Fibroadenomas (n=3) 54 39 121
Case 122 44 35 77 (50% epithelial cells)a
Case 124 45 26 164 (20% epithelial cells)a
Case 86 72 56 121 (50% epithelial cells)a
Hamartoma 80 59 105 (50% epithelial cells)a
Ductal hyperplasiab (case 41) 67 18 48 (60% epithelial cells)a
a Estimated from histological examination ofstained sections. b Proliferative lesion with acombination ofintraductal hyperplasiawithoutatypia,
sclerosing adenosis and fibrocystic disease.
Table II Levels of high-M, tms in breast-derived cell lines and in fibroblasts (relative integrated optical density, tm 5= 100)
Cell line tmI tm 2 tm 3
MCF-7 2.4 2.4 27
T47D 2.0 4.0 41
BT 549 27 2.1 29
SK-BR-3 5.7 4.8 32
MDA-MB-134 0.7 0.7 5.3
MDA-MB-231 1.2 0.4 0.8
ZR-75-30 0.6 1.2 1.2
Mean values 5.7 2.2 20
578 Bst 66 32 58 (breast derived, non-tumorigenic, fibroblast-like)
WI38 80 17 38 (fibroblast strain)
HDF 76 22 21
v
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Table III Levels of high Mr tms in 12V-H-ras transformed rat embryo fibroblasts
Cell strain tm I tm 2 tm 3 Metastatic capacitya
BRN-l 22 6.3 2.9 + + +
BRN-7 17 4.5 2.1 +++
BRN-6 10 0.4 0.4 + +
BRN-2 0.4 0.9 1.3 +
BRN-4 0.4 1.5 0.5 +
Embryo fibroblasts 154 99 22
a Data from Engel et al. (1993): + + +, all mice showed massive (> 30 nodes per section) lung metastases after i.v. injection of 2 x 105 cells;
+ +, all mice showed 10-30 metastases per section; + most mice show no or few (< 10) colonies/section.
Hs-578 Bst cells and in human fibroblasts (Table II). Whereas
tm 1 and tm 2 levels were similar in Hs-578 Bst cells and
fibroblasts, they were lower in the breast carcinoma cell lines.
Similar to the observations made in tumour tissue, tm 3
expression in cell lines varied considerably (0.8-41 units).
Four of the cell lines showed higher levels of tm 3 than
human diploid fibroblasts (HDFS).
Higher levels of tm 1 in node-positive compared with node-
negative breast carcinomas
Tm levels were compared in primary carcinomas from cases
with or without lymph node metastases. As shown in Figure
3, tm 1 levels were 1.7-fold higher in node-positive compared
with node-negative tumours. This difference was statistically
significant at the level of P<0.05 (Mann-Whitney). No
difference was observed in the levels of tm 2 or tm 3 between
node-positive and -negative tumours.
Tm I expression in 12V-H-ras transformed rat fibroblasts
Tropomyosin isoform expression was examined in rat
fibroblasts and five 12V-H-ras transformed rat fibroblasts
with varying capacities for experimental metastasis. A
dramatic decrease in the expression of tm 1, tm 2 and tm 3
was observed in all transformed cell lines (Table III).
Interestingly, higher levels of tm 1, 2 and 3 were observed
in the most metastatic cell lines (BRN-1 and BRN-7). The
differences in expression was most pronounced for tm 1. An
intermediate level of tm 1 was observed in the moderately
metastatic BRN-6 cell line.
Discussion
Although alterations in tm isoform expression have been
described in transformed cell lines in several previous studies,
studies of tm expression in human tumour cells in situ are
rare. In the present study, tumour cells were purified from
both non-cancerous breast lesions (including benign tumours)
and from breast carcinomas. Total cell extracts were then
subjected to two-dimensional gel electrophoresis. By this
procedure, we were able to obtain high-resolution polypep-
tide maps from tumour cells and were able to measure the
total (insoluble and soluble) cellular quantitities of tms 1-5.
Our data clearly show that high M, tropomyosins are
down-regulated in breast carcinoma. The levels of tms 1 and
2 were lower in all carcinomas than in any of the non-
malignant tissues examined. Similarly, tm 3 was also lower in
the carcinomas. In three cases, however, higher levels of tm 3
were observed in carcinomas compared with the case of
ductal hyperplasia. We conclude from these results that the
expression of high-Mr tropomyosin isoforms is suppressed
not only in vitro but also in vivo.
Previous studies of tms in transformed fibroblast and
breast carcinoma cell lines have uniformly identified
suppression of high Mr tMs (Hendricks and Weintraub,
1981; Bhattacharya et al., 1988). We were able to reproduce
these results using 12V-H-ras transformed rat embryo
fibroblasts and breast carcinoma cell lines. Strong down-
regulation of all three high-Mr tropomyosin isoforms was
observed in ras-transformed fibroblasts compared with
untransformed cells. In a previous report, Garrels and
Franza (1989) showed that tm 2 is suppressed to an
intermediate level in morphologically SV40 transformed
non-tumorigenic REF52 fibroblast clones (WT2 and WT6)
as compared with tumorigenic clones. We have observed
intermediate levels of tm 2 expression in WT2 cells compared
with 12V-ras transformed rat embryo fibroblasts (our
unpublished observations), confirming this finding. The
levels of high-Mr tropomyosins in in vitro cultured breast
carcinoma cell lines were in the same range as those observed
in tumours, but the average levels were lower. This could
reflect some contamination in tumour samples, or may simply
be a result of cell lines not being representative of primary
tumour material, or that cell lines undergo modifications in
vitro when they are established from primary cells.
Interestingly, the levels of tm 1 were found to be elevated
in primary tumours that had given rise to lymph node
metastases. Tm 1 expression was higher in two strongly
metastatic 12V-ras transformed cell lines compared with three
weakly metastatic lines. This difference was most pronounced
for tm 1. In a previous study (Okuzawa et al., 1994), we
found tm 1 expression in four out of four small-cell lung
carcinomas, but did not detect tm 1 in six out of eight non-
small-cell lung carcinomas. Small-cell lung carcinomas are
known to be highly metastatic, whereas non-small-cell lung
carcinomas are not. These findings raise the possibility that
higher levels of tm 1 may induce cellular motility or affect
other functions that may contribute to metastasis.
Because of the promising possibility of a future use of tm
markers in the field of tumour diagnosis and malignancy
grading, we plan to extend the investigation by examining
additional clinical material representing different stages of
malignant transformation and tumour progression.
Acknowledgements
We thank Drs Martin Backdahl and Goran Wallin at the
Department of Surgery and Eva Edholm at the mammography
unit for the supply of clinical material, and Elina Ericsson at the
Department of Pathology for histopathological examinations. This
work was supported by Cancerf6reningen i Stockholm and
Cancerfonden.
References
ANDERSON NL. (1991). Two-Dimensional Electrophoresis, Operation
of the ISO-DALT System, 2nd edn, pp. 17-97. Large Scale
Biology press: Rockville, MD.
BHATTACHARYA B, CIARDIELLO F, SALOMON DS AND COOPER
HL. (1988). Disordered metabolism of microfilament proteins,
tropomyosin and actin, in mouse mammary epithelial cells
expressing the Ha-RAS oncogene. Oncogene Res., 3, 51-65.
BHATTACHARYA B, PRASAD GL, VALVERIUS EM, SALOMON DS
AND COOPER HL. ((1990). Tropomyosin of human mammary
epithelial cells: consistent defects of expression in mammary
carcinoma cell lines. Cancer Res., 50, 2105-2112.Tropomyosin isoforms in breast carcinoma
B Franzdn et al
913
COOPER HL, BHATTACHARYA B, BASSIN RH AND SALOMON DS.
(1987). Suppression ofsynthesis and utilization oftropomyosin in
mouse and rat fibroblasts by transforming growth factor alpha: a
pathway in oncogene action. Cancer Res., 47, 4493-4500.
ENGEL G, POPOWICZ P, MARSHALL H, FRANZEN B, OKUZAWA K,
AUER G AND LINDER S. (1993). Limited invasive capacity of
plt+ras transformed rat fibrosarcoma cells effective in experi-
mental metastasis. Int. J. Oncology, 3, 457-465.
FRANZEN B, OKUZAWA K, LINDER S, KATO H AND AUER G.
(1993). Non-enzymatic extraction of cells from clinical tumour
material for analysis of gene expression by two-dimensional gel
electrophoresis. Electrophoresis, 14, 382-390.
GARRELSJIAND FRANZA BJ. (1989). Transformation-sensitive and
growth-related changes of protein synthesis in REF52 cells. A
two-dimensional gel analysis of SV40-, adenovirus-, and Kirsten
murine sarcoma virus-transformed rat cells using the REF52
protein database. J. Biol. Chem., 264, 5299-5312.
GARRELS JI, FARRAR JT AND BURWELL CB. (1984). The QUEST
system for computer-analyzed two-dimensional gel electrophor-
esis ofproteins. In Celis JE and Bravo R. (eds.) Two-dimensional
Gel Electrophoresis of Proteins: Methods and Applications.
Academic Press: New York.
GLUCK UD, KWIATKOWSKI J AND BEN-ZE'EV A. (1993).
Suppression of tumorigenicity of simian virus 40-transformed
3T3 cells transfected with a-actinin cDNA. Proc. Natl Acad. Sci.
USA, 90, 383-387.
HENDRICKS M AND WEINTRAUB H. (1981). Tropomyosin is
decreased in transformed cells. Proc. Natl Acad. Sci. USA, 78,
5633 -5637.
LEES-MILLER JP AND HELFMAN DM. (1991). The molecular basis
for tropomyosin isoform diversity. Bio Essays, 13, 429-437.
MATSUMURA F AND YAMASHIRO-MATSUMURA S. (1985).
Purification and characterization of multiple isoforms of
tropomyosin from rat cultured cells. J. Biol. Chem., 260,
13851 - 13859.
OKUZAWA K, FRANZEN B, LINDHOLM J, LINDER S, HIRANO T,
BERGMAN T, EBIHARA Y, KATO H AND AUER G. (1994).
Characterization of gene expression in clinical lung cancer
materials by two-dimensional polyacrylamide gel electrophor-
esis. Electrophoresis, 15, 382-390.
PRASAD GL, FULDNER RAAND COOPER HL. (1993). Expression of
transduced tropomyosin 1 cDNA suppresses neoplastic growth of
cells transformed by the ras oncogene. Proc. NatlAcad. Sci. USA,
90, 7039-7043.
RAZAANDGEIGER B. (1982). Altered organization ofcell-substrate
contacts and membrane associated cytoskeleton in tumor cell
variants exhibiting different metastatic capabilities. Cancer Res.,
42, 5183-5190.
TAKENAGA K AND MASUDA A. (1994). Restoration of microfila-
ment bundle organization in v-raf-transformed NRK cells after
transduction with tropomyosin 2 cDNA. Cancer Lett, 87, 47-53.
VANDERKERCKHOVE J, BAUW GK, VANCOMPERNOLLE B,
HONORE B AND CELIS J. (1990). Comparative two dimensional
gel analysis and microsequencing identifies gelsolin as one of the
most prominent downregulated markers of transformed human
fibroblasts and epithelial cells. J. Cell. Biol., 111, 95-102.